The Division Bench of the Delhi High Court (HC), on October 16, 2024, reinstated the injunction preventing Zydus from manufacturing, selling, or marketing its breast cancer drug Sigrima, a biosimilar ...

Legal battle over Zydus' biosimilar breast cancer drug could impact generic competition, Supreme Court refuses interim relief.

In July, a single-judge bench of the Delhi High Court restrained Zydus Lifesciences from selling its breast cancer drug in ...